1687 related articles for article (PubMed ID: 8635191)
1. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
[TBL] [Abstract][Full Text] [Related]
2. The antitumor effect of tumor-draining lymph node cells activated by both anti-CD3 monoclonal antibody and activated B cells as costimulatory-signal-providing cells.
Okamoto T; Harada M; Shinomiya Y; Matsuzaki G; Nomoto K
Cancer Immunol Immunother; 1995 Mar; 40(3):173-81. PubMed ID: 7728776
[TBL] [Abstract][Full Text] [Related]
3. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
[TBL] [Abstract][Full Text] [Related]
4. Specific immunotherapy with tumour-draining lymph node cells cultured with both anti-CD3 and anti-CD28 monoclonal antibodies.
Harada M; Okamoto T; Omoto K; Tamada K; Takenoyama M; Hirashima C; Ito O; Kimura G; Nomoto K
Immunology; 1996 Mar; 87(3):447-53. PubMed ID: 8778032
[TBL] [Abstract][Full Text] [Related]
5. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
6. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
Gajewski TF
J Immunol; 1996 Jan; 156(2):465-72. PubMed ID: 8543795
[TBL] [Abstract][Full Text] [Related]
7. Costimulation light: activation of CD4+ T cells with CD80 or CD86 rather than anti-CD28 leads to a Th2 cytokine profile.
Broeren CP; Gray GS; Carreno BM; June CH
J Immunol; 2000 Dec; 165(12):6908-14. PubMed ID: 11120816
[TBL] [Abstract][Full Text] [Related]
8. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
9. Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer.
Malone CC; Schiltz PM; Mackintosh AD; Beutel LD; Heinemann FS; Dillman RO
Cancer Biother Radiopharm; 2001 Oct; 16(5):381-90. PubMed ID: 11776755
[TBL] [Abstract][Full Text] [Related]
10. CD28, TNF receptor, and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells.
Hu HM; Winter H; Ma J; Croft M; Urba WJ; Fox BA
J Immunol; 2002 Nov; 169(9):4897-904. PubMed ID: 12391201
[TBL] [Abstract][Full Text] [Related]
11. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
Le HK; Graham L; Miller CH; Kmieciak M; Manjili MH; Bear HD
Cancer Immunol Immunother; 2009 Oct; 58(10):1565-76. PubMed ID: 19198835
[TBL] [Abstract][Full Text] [Related]
12. Reactivation of murine tumour-infiltrating lymphocytes with solid-phase anti-CD3 antibody: in vitro cytokine production is associated with in vivo efficacy.
Goedegebuure PS; Zuber M; Leonard-Vidal DL; Burger UL; Cusack JC; Chang MP; Douville LM; Eberlein TJ
Surg Oncol; 1994 Apr; 3(2):79-89. PubMed ID: 7952395
[TBL] [Abstract][Full Text] [Related]
13. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
[TBL] [Abstract][Full Text] [Related]
14. Lymphokine production by human melanoma tumor-infiltrating lymphocytes.
Salmeron MA; Morita T; Seki H; Platsoucas CD; Itoh K
Cancer Immunol Immunother; 1992; 35(3):211-7. PubMed ID: 1386286
[TBL] [Abstract][Full Text] [Related]
15. Production and characterization of tumor infiltrating lymphocyte clones derived from B16-F10 murine melanoma.
Maeda K; Lafreniere R; Jerry LM
J Invest Dermatol; 1991 Aug; 97(2):183-9. PubMed ID: 2071934
[TBL] [Abstract][Full Text] [Related]
16. Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12.
Ulchaker J; Panuto J; Rayman P; Novick A; Elson P; Tubbs R; Finke JH; Bukowski RM
J Immunother; 1999 Jan; 22(1):71-9. PubMed ID: 9924702
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
[TBL] [Abstract][Full Text] [Related]
18. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
19. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
20. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
